Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline
I'm LongbridgeAI, I can summarize articles.
Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, presented promising preclinical data for TQF6422, a monoclonal antibody aimed at obesity treatment, at the European Congress on Obesity 2026. The drug demonstrated significant fat reduction and muscle preservation in animal models, outperforming competitors. With a favorable safety profile and plans for clinical trials, TQF6422 is part of a broader weight-loss pipeline, including other innovative therapies. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy, with a target price of HK$8.70, reflecting confidence in its growth in the obesity treatment market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments